国际肿瘤学杂志 ›› 2020, Vol. 47 ›› Issue (9): 546-549.doi: 10.3760/cma.j.cn371439-20200527-00075

• 综述 • 上一篇    下一篇

Legumain在恶性肿瘤中的研究进展

颜丙芳, 孟玮, 柏雪莲()   

  1. 滨州医学院附属医院临床医学实验室 256603
  • 收稿日期:2020-05-27 修回日期:2020-07-09 出版日期:2020-09-08 发布日期:2020-10-27
  • 通讯作者: 柏雪莲 E-mail:xuelianbai99@163.com
  • 基金资助:
    山东省医药卫生科技发展计划(2017WS884);滨州医学院科研计划与科研启动基金(BY2017KYQD12)

Progress of Legumain in malignant tumors

Yan Bingfang, Meng Wei, Bai Xuelian()   

  1. Clinical Medicine Laboratory, Binzhou Medical University Hospital, Binzhou 256603, China
  • Received:2020-05-27 Revised:2020-07-09 Online:2020-09-08 Published:2020-10-27
  • Contact: Bai Xuelian E-mail:xuelianbai99@163.com
  • Supported by:
    Medicine and Health Science Technology Development Project of Shandong Province(2017WS884);Binzhou Medical University Scientific Research Initiation Fund(BY2017KYQD12)

摘要:

天冬酰胺内肽酶Legumain是半胱氨酸蛋白酶C13家族的新成员,在体内发挥多方面的作用。近年来,研究发现Legumain在多种肿瘤组织中高表达,并通过多种机制促进肿瘤细胞的增殖、肿瘤的侵袭转移和血管生成等。对Legumain的深入研究将有利于阐明恶性肿瘤的发病及进展机制,为肿瘤靶向治疗提供新靶点。

关键词: 肿瘤, 分子靶向治疗, 机制, Legumain

Abstract:

Legumain, also called asparaginyl endopeptidase, is one new member of the cysteine protease C13 family and plays various roles in human. In recent years, studies have displayed that Legumain is over expressed in a variety of tumors types and promotes the proliferation of tumor cells, tumor invasion and metastasis as well as angiogenesis through varied mechanisms. Further investigation of Legumain will be helpful to elucidate the pathogenesis and progression mechanism of malignant tumors and provide new molecular for targeted therapy of tumors.

Key words: Neoplasms, Molecular targeted therapy, Mechanism, Legumain